Hikma Pharmaceuticals (HIK) Meet The Management presentation summary

Strategic business overview

• Rebranded generics division as Hikma Rx to emphasize focus on differentiated and complex prescription medicines.

• Operates three business divisions: Hikma Rx, Injectables, and Branded, each contributing significantly to revenue and profit.

• US-based manufacturing and distribution centers provide broad reach and efficient supply to North American markets.

• Strong emphasis on quality, with a decade of excellent audit and inspection results and zero FDA observations in recent years.

• Strategic investments in capacity, technology, and R&D underpin growth ambitions and market leadership.

Financial and operational performance

• Hikma Rx contributed 33% of 2024 revenue and 21% of core operating profit; Injectables led with 42% of revenue and 56% of profit.

• Group achieved a 7% CAGR in both core revenue and core operating profit over the past five years.

• Contract manufacturing (CMO) business is growing, expected to exceed 20% of Hikma Rx revenue by 2030.

• Strategic geographic expansion in the US, Canada, and Europe, with double-digit growth in key markets.

• Investments of over $1.5 billion in CAPEX planned to enhance and expand manufacturing capacity globally.

R&D and product pipeline

• Robust pipeline with 56% of assets in development, focusing on complex generics, respiratory, and nasal drug-device combinations.

• Emphasis on first-to-file Paragraph IV applications for high-value launches and market exclusivity.

• Investing in differentiated respiratory platforms, including generic versions of Respimat, Ellipta, and low global warming potential inhalers.

• Expanded R&D footprint in the US, Croatia, and Jordan, leveraging global expertise for complex product development.

• Increased focus on higher-barrier products such as modified release, nasal sprays, and novel 505(b)(2) products.